New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
09:04 EDTHALOHalozyme resumes enrollment and dosing of patients for PEGPH20 Phase 2 trial
Halozyme Therapeutics announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
08:24 EDTHALOHalozyme PEGPH20 data supports ongoing work
Subscribe for More Information
07:57 EDTHALOHalozyme an underappreciated story with catalysts, says UBS
Subscribe for More Information
April 17, 2015
07:14 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
April 16, 2015
07:10 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information
April 14, 2015
07:10 EDTHALOHalozyme management to meet with UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use